Belgian Metals and Mining Stock News

UCB (ENXTBR:UCB) has released new real world and clinical data from its epilepsy and myasthenia gravis portfolios at major neurology conferences. Interim survey results highlight how developmental and epileptic encephalopathies affect daily life, including for Lennox Gastaut and Dravet syndromes. Fresh findings on ZILBRYSQ (zilucoplan) focus on patient administration options for people living with generalized myasthenia gravis. For investors following ENXTBR:UCB, this update fits squarely...

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...

argenx (ENXTBR:ARGX) has drawn fresh attention after completing a key chronic inflammatory demyelinating polyneuropathy, or CIDP, switch study, a clinical milestone that shapes expectations around the next steps for its efgartigimod therapy. See our latest analysis for argenx. At a share price of €677.0, argenx has seen a 10.30% 1 month share price return but is still showing a 6.47% decline year to date, while its 1 year total shareholder return of 28.37% and 5 year total shareholder return...

Earnings snapshot and why it matters for investors Spadel (ENXTBR:SPA) just released full year 2025 results, reporting sales of €399.52 million and net income of €51.19 million. This compares with sales of €357.29 million and net income of €41.03 million a year earlier. See our latest analysis for Spadel. The latest earnings release appears to have aligned with positive sentiment, with a 1-day share price return of 2.56% and a year to date share price return of 35.59%. The 1-year total...

Recently, argenx reported the completion of a key CIDP switch study for its efgartigimod therapy, marking a meaningful clinical milestone in its autoimmune portfolio. This progress in CIDP strengthens the case for efgartigimod as a potentially broader platform therapy across neuromuscular autoimmune indications. Next, we will examine how completion of the CIDP switch study might influence argenx’s investment narrative and outlook for efgartigimod. Capitalize on the AI infrastructure...

Fagron (ENXTBR:FAGR) put acquisitions back in focus in its Q1 2026 trading update, pairing 10% topline growth with confirmation that recent deals, including Pharmavit in the Netherlands, are being integrated as planned. See our latest analysis for Fagron. The share price sits at €22.5, with a 3.45% year to date share price return and a 17.69% one year total shareholder return, which hints that investors are gradually warming to Fagron's growth and acquisition story. If Fagron's acquisition...

Solvac S.A.'s ( EBR:SOLV ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Retail Estates (ENXTBR:RET) is expanding beyond Belgium and the Netherlands after acquiring a retail park in Île De France, giving investors a new reference point for assessing its focus on out of town retail property. See our latest analysis for Retail Estates. The French acquisition comes at a time when Retail Estates’ share price has shown firm upward momentum, with a 30 day share price return of 7.45% and a year to date share price return of 10.64%. The 1 year total shareholder return of...

Why Azelis Group is on investors’ radar Azelis Group (ENXTBR:AZE) has caught investor attention after a recent share price move, with the stock showing a mix of short term gains and longer term weakness that raises fresh questions about its current valuation. See our latest analysis for Azelis Group. The recent rally, including a 23.88% 30 day share price return and 5.37% 7 day share price return to €9.415, comes against a much weaker backdrop, with a 36% 1 year total shareholder return...

Why Anheuser-Busch InBev (ENXTBR:ABI) is on investors’ radar Anheuser-Busch InBev (ENXTBR:ABI) has caught investor attention after recent share price moves, with the stock showing positive returns over the past week, month and past 3 months, alongside double digit annual revenue and net income growth. See our latest analysis for Anheuser-Busch InBev. Looking beyond the latest move, the 90 day share price return of 13.93% and year to date share price return of 18.46% suggest building momentum,...

Fagron reported strong first quarter revenue growth, supported by recent mergers and acquisitions. The company completed and integrated the Pharmavit acquisition during the quarter. Operations in Latin America contributed meaningfully to first quarter performance. For investors watching ENXTBR:FAGR, the latest update adds fresh context to a share price currently around €22.5. The stock is up 17.7% over the past year and 31.3% over three years, while the five year return of 28.2% suggests...

BlackRock, Inc. disclosed that its direct voting rights in Umicore (ENXTBR:UMI) moved above the 5% threshold, then later fell back below 5%, within a short period. The changes were reported through regulatory filings, highlighting shifts in a major institutional investor's position in the company. Crossing the 5% level triggers mandatory disclosure rules, which can draw market attention to institutional ownership in Umicore. Umicore operates in materials technology and recycling, with...

Fluxys Belgium: recent performance and context Fluxys Belgium (ENXTBR:FLUX) has attracted attention after its share price closed at €21. The stock shows a roughly flat move over the past month, with a gain of about 13% over the past 3 months. See our latest analysis for Fluxys Belgium. Recent moves have been mixed, with a 1-day share price return of 2.78% decline and a 90-day gain of 12.9%. The 1-year total shareholder return is 14.62%, while the 5-year total shareholder return is 25.7%...

Budweiser, part of Anheuser-Busch InBev, has launched a limited-edition FIFA World Cup Anniversary Pack marking 40 years as the tournament's official beer sponsor. The campaign introduces a nostalgia themed global marketing platform with collectible packaging and digital experiences. The push targets major non US markets and is timed to build fan engagement ahead of the 2026 World Cup. Anheuser-Busch InBev (ENXTBR:ABI) is using this anniversary launch to put fresh attention on Budweiser,...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Groupe Bruxelles Lambert (ENXTBR:GBLB) has wrapped up FY 2025 with fourth quarter revenue of €1.3 billion and a basic EPS loss of €2.40, while trailing twelve month figures show revenue of €6.2 billion and a basic EPS loss of €2.53. Over recent periods, revenue has ranged between €1.3 billion and €1.9 billion per quarter, with basic EPS moving from a profit of €0.76 in Q1 2025 to successive losses later in the year. This has left margins under pressure and kept profitability firmly in focus...

Norse Wind vessel puts DEME Group (ENXTBR:DEME) in focus DEME Group (ENXTBR:DEME) has drawn fresh investor attention after christening the Norse Wind, a new offshore wind installation vessel equipped with a 3,200-tonne crane and a hybrid power system. The ship is built to install larger next generation turbines and operate in harsher offshore conditions. Its hybrid setup targets more than 70% emission reductions. Norse Wind already carries long term contracts for major European offshore wind...

Why Solvay (ENXTBR:SOLB) Is On Investors’ Radar Today Solvay (ENXTBR:SOLB) has caught investor attention after recent share price moves, with the stock closing at €27.18 and showing mixed return patterns over the past week, month and past 3 months. See our latest analysis for Solvay. Recent trading has been steady rather than dramatic, with a 6.8% 1 month share price return and a slightly negative year to date move, while the 5 year total shareholder return of 58.6% reflects a stronger longer...

UCB (ENXTBR:UCB) has put BIMZELX center stage at the 2026 American Academy of Dermatology meeting, releasing three year and four year data across hidradenitis suppurativa and plaque psoriasis that emphasizes durable clinical responses. See our latest analysis for UCB. UCB's recent dermatology data drop comes after a strong run in the shares, with a year to date share price return of 14.35% and a very large 5 year total shareholder return of 251.93%. This suggests momentum has been building...

As European markets experience a boost in sentiment due to hopes of a shorter Middle East conflict, indices like the STOXX Europe 600 and Germany's DAX have shown notable gains. In this environment, identifying stocks that may be trading below their estimated value can offer opportunities for investors looking to capitalize on potential market inefficiencies.

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...

Syensqo (ENXTBR:SYENS) has wrapped up FY 2025 with fourth quarter revenue of €1,384 million and basic EPS of a €1.61 loss, while the trailing twelve months show revenue of €5,969 million and basic EPS of a €0.85 loss. Over recent quarters, revenue has moved from €1,662 million in Q4 2024 to €1,678 million in Q1 2025, €1,639 million in Q2 2025, €1,558 million in Q3 2025, and €1,384 million in Q4 2025, with EPS swinging between a €1.28 loss and a €0.49 gain before landing at a €1.61 loss this...

As European markets navigate the complexities of Middle East conflicts and energy price volatility, indices like the STOXX Europe 600 have shown modest gains, reflecting a cautious optimism amidst geopolitical uncertainties. In these fluctuating times, dividend stocks can offer investors a measure of stability and potential income, making them an appealing consideration for those looking to balance risk with consistent returns.

Syensqo share performance snapshot Syensqo (ENXTBR:SYENS) has attracted attention after a recent move that left the stock about 2% higher over the past month, yet showing a roughly 28% decline over the past 3 months. Over the past year, Syensqo’s total return is about 20% lower, while year to date performance shows a similar decline of around 29%. These moves provide context for assessing its current valuation. See our latest analysis for Syensqo. Syensqo’s share price, now at €49.48, has...